90326-54-8

Basic information

• Product Name: 1-(5-bromo-2-methylphenyl)ethanone
• Synonyms: 1-(5-bromo-2-methylphenyl)ethanone
• CAS NO: 90326-54-8
• Molecular Formula: C₉H₉BrO
• Molecular Weight: 213.07116
• Mol File: 90326-54-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(5-bromo-2-methylphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-bromo-2-methylphenyl)ethanone(90326-54-8)
• EPA Substance Registry System: 1-(5-bromo-2-methylphenyl)ethanone(90326-54-8)

Safety Data

• Hazardous Substances Data: 90326-54-8(Hazardous Substances Data)

Usage

General Description

1-( 5-bromo-2-methyphenyl)ethanone is a chemical compound that is also known as 1-(5-bromo-2-methylphenyl) ethan-1-one. It is a substituted aromatic ketone with a molecular formula of C9H9BrO. 1-(5-bromo-2-methylphenyl)ethanone is commonly used in organic synthesis and chemical research. It is typically synthesized from 5-bromo-2-methylacetophenone using a variety of methods, such as Friedel-Crafts acylation. 1-( 5-bromo-2-methyphenyl)ethanone is also used as a building block in the production of pharmaceuticals, agrochemicals, and various other chemical products. Its key properties include its high purity and stability, making it a valuable component in many laboratory and industrial processes.

Upstream product

• 917-64-6 methyl magnesium iodide 
• 156001-51-3 3-Bromo-6-methyl-benzonitrile 
• 939-83-3 2-cyano-4-nitrotoluene 
• 50670-64-9 3-cyano-4-methylaniline 
• 842135-03-9 5-bromo-N-methoxy-N,2-dimethylbenzamide 
• 676-58-4 methylmagnesium chloride 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 21900-41-4 5-bromo-2-methylbenzoyl?chloride 
• 74-88-4 methyl iodide 
• 90050-59-2 5-bromo-2-methylbenzaldehyde 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1426165-37-8 C₂₂H₂₂O 
• 1161497-35-3 4-bromo-2-ethyl-1-methylbenzene 
• 1426165-19-6 C₂₅H₂₇NO₂S 
• 1426165-20-9 C₂₄H₂₇NS 
• 1616929-88-4 N-(2,6-difluoro-phenyl)-1-methyl-5-(2-methyl-5-pyrimidin-5-yl-phenyl)-1H-pyrazole-3-carboxylic acid amide 
• 1616930-17-6 4-amino-N-(3,5-difluoro-pyridin-4-yl)-1-methyl-5-(2-methyl-5-oxazol-2-yl-phenyl)-1H-pyrazole-3-carboxylic acid amide 
• 1616930-27-8 C₁₄H₁₅BrN₂O₂ 
• 1616929-76-0 N-(3-fluoro-pyridin-4-yl)-1-methyl-5-(2-methyl-5-thiazol-2-yl-phenyl)-1H-pyrazole-3-carboxylic acid amide 
• 1616930-28-9 C₁₇H₁₇N₃O₂S 
• 1616930-30-3 C₁₇H₁₇N₃O₃ 
• 1616930-29-0 C₁₅H₁₃N₃O₂S 
• 1616930-31-4 C₁₅H₁₃N₃O₃ 
• 1616930-40-5 C₁₉H₁₉N₃O₂ 
• 1616930-41-6 C₁₇H₁₅N₃O₂ 

Relevant articles and documents

Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation

In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens with a cell-based nuclear factor κB (NF-κB) reporter assay, we identified a sulfamoyl benzamidothiazole bearing compound 1 that demonstrated a sustained activation of NF-κB after a primary stimulus with a Toll-like receptor (TLR)-4 agonist, lipopolysaccharide (LPS). Here, we explore systematic structure–activity relationship (SAR) studies on compound 1 that indicated the sites on the scaffold that tolerated modification and yielded more potent compounds compared to 1. The selected analogs enhanced release of immunostimulatory cytokines in the human monocytic cell line THP-1 cells and murine primary dendritic cells. In murine vaccination studies, select compounds were used as co-adjuvants in combination with the Food and Drug Administration approved TLR-4 agonistic adjuvant, monophosphoryl lipid A (MPLA) that showed significant enhancement in antigen-specific antibody titers compared to MPLA alone. Additionally, our SAR studies led to identification of a photoaffinity probe which will aid the target identification and mechanism of action studies in the future.

PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF

The present invention comprises compounds of Formula I and their use in the inhibition of cell proliferation in therapeutic treatments. Pharmaceutical compositions comprising at least one compound of Formula I and at least one pharmaceutical excipient are disclosed, as well as methods of using compounds of Formula I and pharmaceutical compositions thereof for treatment of hyper-proliferative diseases and other disorders.

PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS

The Invention relates to pyrazolyl-based carboxamide compounds of formula (l) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.